NasdaqGM - Delayed Quote USD

Cerus Corporation (CERS)

1.6400 0.0000 (0.00%)
At close: April 18 at 4:00 PM EDT

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. William M. Greenman President, CEO & Director 1.33M 627k 1967
Mr. Kevin D. Green VP of Finance & CFO 748.49k -- 1972
Mr. Vivek K. Jayaraman Chief Operating Officer 861.67k -- 1975
Ms. Chrystal Jensen Chief Legal Officer & General Counsel 692.16k -- 1971
Dr. Richard J. Benjamin Chief Medical Officer 719.74k -- 1960
Dr. Laurence M. Corash Co-Founder & Chief Scientific Officer 697.77k 191.79k 1944
Ms. Lori L. Roll VP of Administration & Corporate Secretary -- -- --
Mr. Matthew M. Notarianni Senior Director of Investor Relations -- -- --
Lainie Corten Vice President of Global Marketing -- -- --
Ms. Alicia Goodman Chief Human Resources Officer -- -- --

Cerus Corporation

1220 Concord Avenue
Suite 600
Concord, CA 94520
United States
925 288 6000 https://www.cerus.com
Sector: 
Healthcare
Industry: 
Medical Devices
Full Time Employees: 
625

Description

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.

Corporate Governance

Cerus Corporation’s ISS Governance QualityScore as of April 1, 2024 is 5. The pillar scores are Audit: 6; Board: 3; Shareholder Rights: 7; Compensation: 5.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 02, 2024
Cerus Corporation Earnings Call

Related Tickers

RCEL AVITA Medical, Inc.
8.87
-5.44%
 
CTSO Cytosorbents Corporation
0.8010
+1.39%
 
MASS 908 Devices Inc.
5.60
+0.18%
 
OM Outset Medical, Inc.
2.2500
+4.17%
 
BSGM BioSig Technologies, Inc.
1.5400
-5.52%
 
MOTS Motus GI Holdings, Inc.
0.0700
-7.89%
 
ICCM IceCure Medical Ltd
1.2300
-4.65%
 
PACB Pacific Biosciences of California, Inc.
1.4600
+4.29%
 
AIMD Ainos, Inc.
1.0300
-0.96%
 
LNSR LENSAR, Inc.
3.1400
+2.61%